NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Launched by RIGSHOSPITALET, DENMARK · Oct 23, 2007
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
In addition to the details above we will also explore
* the relationship of the post-HD-MTX MRD-levels with the dose of 6MP, TPMT-activity, DNA-6TGN, E-6TGN, E-MeMP, E-MTX, and presence of ASP-antibodies,
* the early development of anti-ASP antibodies during continuous PEG-ASP therapy.
The study could improve the understanding of the pharmacodynamics of the 6MP/HD-MTX interaction in combination with PEG-ASP.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • B-lineage ALL
- • 1-17.9 years
- • WBC \<100, clinical remission obtained day 2
- • Written consent to participation.
- Exclusion Criteria:
- • t(9;22)
- • Hypodiploidy
- • 11q23-aberrations
- • TPMT-deficiency
- • Intolerance to MTX or 6MP
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Odense, , Denmark
Gothenburg, , Sweden
Patients applied
Trial Officials
Kjeld Schmiegelow, M.D.
Study Chair
Pediatric Clinic II, RIgshospitalet, Copenhagen, DK-2100
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials